Results 261 to 270 of about 118,682 (313)
Some of the next articles are maybe not open access.
Cerebrovascular Diseases, 2000
The current goal of acute stroke therapy is to restore cerebral perfusion and to protect cerebral tissue before the development of an irreversible damage. This latter is due to the duration and the severity of cerebral ischemia [1]. Recanalization operated by thrombolysis represents the most intuitive and effective treatment of acute cerebral ischemia.
MOSTARDINI C +5 more
openaire +3 more sources
The current goal of acute stroke therapy is to restore cerebral perfusion and to protect cerebral tissue before the development of an irreversible damage. This latter is due to the duration and the severity of cerebral ischemia [1]. Recanalization operated by thrombolysis represents the most intuitive and effective treatment of acute cerebral ischemia.
MOSTARDINI C +5 more
openaire +3 more sources
Neuroprotection in Schizophrenia
The Journal of Clinical Psychiatry, 2006Longitudinal and structural neuroimaging studies show that patients with schizophrenia that converted to psychosis were found to have progressive gray matter loss in the cortex. Gray matter loss was also associated with functional decline. While the underlying mechanisms of gray matter loss remain uncertain, evidence of improved outcomes suggests ...
L Fredrik, Jarskog, Jeffrey A, Lieberman
openaire +2 more sources
Medical Clinics of North America, 1999
Though effective symptomatic therapies for Parkinson's disease exist, currently no treatment is proven to slow the progression of the underlying disease. Our growing understanding of the mechanisms of neuronal models, however, offers hope that neuroprotective strategies will soon be a standard part of the treatment of PD.
D K, Simon, D G, Standaert
openaire +2 more sources
Though effective symptomatic therapies for Parkinson's disease exist, currently no treatment is proven to slow the progression of the underlying disease. Our growing understanding of the mechanisms of neuronal models, however, offers hope that neuroprotective strategies will soon be a standard part of the treatment of PD.
D K, Simon, D G, Standaert
openaire +2 more sources
Neuroprotection by tetracyclines
Trends in Pharmacological Sciences, 2004The neuroprotective properties of tetracyclines have been clearly established in rodent models of acute and chronic neurodegeneration during the past few years. Recent findings have provided novel insights into the molecular and cellular mechanisms of protection of neurons and oligodendrocytes by tetracyclines.
María, Domercq, Carlos, Matute
openaire +2 more sources
Strategies for Neuroprotection
Journal of Glaucoma, 2001While glaucoma may be a better candidate for the implementation of neuroprotective strategies than more acute CNS diseases, the failure of clinical neuroprotective trials in stroke should prompt both clinical and basic researchers studying glaucoma to develop better methods to test these agents in animal models, as well as improve methods to quantify ...
openaire +2 more sources
Expert Opinion on Investigational Drugs, 2001
The beneficial effect of beta-hydroxy-beta-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) in primary prevention of coronary artery disease in those with hypercholesterolaemia and in secondary prevention in those with established coronary vascular disease are now well known.
N, Delanty, C J, Vaughan, N, Sheehy
openaire +2 more sources
The beneficial effect of beta-hydroxy-beta-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) in primary prevention of coronary artery disease in those with hypercholesterolaemia and in secondary prevention in those with established coronary vascular disease are now well known.
N, Delanty, C J, Vaughan, N, Sheehy
openaire +2 more sources